Life Sciences

Maynard pharmaceutical company Citius Pharmaceuticals said a merger between the former Citius Pharmaceuticals LLC and Trail One Inc. is now complete.

ReWalk Robotics of Marlborough said it had closed its initial public offering of 3.45 million shares of stock, which includes 3 million offered on Monday and an additional 450,000 offered through an underwriters' option to purchase additional shares, the company said Wednesday

RXi Pharmaceuticals Corp. of Marlborough said it has received a new patent on a delivery system for the treatment diseases with an inflammatory component.

Marlborough-based Boston Scientific Corp. (BSX) has received approval to sell its system designed to treat tremor disorders in the European Union, the company announced Wednesday.

Shares of stock in ReWalk Robotics of Marlborough gained more than 13 percent Friday, the same day the manufacturer of robotic exoskeletons for people with spinal cord injuries launched its initial public offering.

AbbVie, a Chicago-based company with a research and development facility in Worcester, announced Thursday that results from...

Saying it has been unable to raise capital to continue operations, cardiac and vascular medical device company PLC Systems Inc. of Milford has proposed merging with a California company and selling its RenalGuard operations to a debtholder, according to a statement and a filing with the U.S. Securities and Exchange Commission (SEC). Shareholders will vote on these measures at an annual, special meeting of shareholders at the Doubletree Hotel in Milford on Sept. 18, the company said last week.

General Electric has settled on Marlborough as the home of its health care and life sciences division, the company announced Wednesday morning.

Boston Scientific of Marlborough and a Japanese firm will jointly develop a new product that will be used in Boston Scientific's Polaris Multi-Modality Imaging System that's used to treat heart patients.

RXi Pharmaceuticals Corp., a clinical-stage biotechnology company based in Marlborough, reported that its net losses held steady at $2 million in the second quarter compared to the same period a year ago.